BIOMAT Database Logo BIOMAT Database Logo

Decrease in the graft rejection rate and improvement in survival after marrow transplantation for severe aplastic anemia. 1979

R Storb

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000741 Anemia, Aplastic A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. Anemia, Hypoplastic,Aplastic Anaemia,Aplastic Anemia,Anaemia, Aplastic,Aplastic Anaemias,Aplastic Anemias,Hypoplastic Anemia,Hypoplastic Anemias
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

R Storb
[Second allogenic bone marrow transplantation after late graft rejection in a patient with severe aplastic anemia].
January 2000, Vojnosanitetski pregled,
R Storb
Late graft rejection following allogeneic bone marrow transplantation in aplastic anemia.
June 2002, Transplantation proceedings,
R Storb
Pregnancy after bone marrow transplantation for severe aplastic anemia.
October 1987, Bone marrow transplantation,
R Storb
Bone marrow transplantation for severe aplastic anemia.
December 1993, Journal of the Formosan Medical Association = Taiwan yi zhi,
R Storb
[Bone marrow transplantation for severe aplastic anemia].
January 1998, Medicina,
R Storb
5-year survival after bone marrow transplantation for aplastic anemia.
January 1998, Journal of insurance medicine (New York, N.Y.),
R Storb
Aplastic anemia after bone marrow transplantation for severe combined immunodeficiency.
January 1979, Haematology and blood transfusion,
R Storb
Allogeneic stem cell transplantation for severe aplastic anemia: graft rejection remains a problem.
February 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,
R Storb
Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia.
April 1999, Bone marrow transplantation,
R Storb
Excellent long-term survival after allogeneic marrow transplantation in patients with severe aplastic anemia.
June 1997, Bone marrow transplantation,
Copied contents to your clipboard!